Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
about
Generation of novel cytoplasmic forms of protein tyrosine phosphatase epsilon by proteolytic processing and translational controlSox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cellsTRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodiesRole for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycleWnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradationCells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survivalThe tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentinProteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2Binding of LARP6 to the conserved 5' stem-loop regulates translation of mRNAs encoding type I collagenThe selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic dosesProteasome inhibition by fellutamide B induces nerve growth factor synthesisA novel mechanism for the regulation of amyloid precursor protein metabolismSelective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitroFunctional importance of the anaphase-promoting complex-Cdh1-mediated degradation of TMAP/CKAP2 in regulation of spindle function and cytokinesis.Endoplasmic reticulum degradation impedes olfactory G-protein coupled receptor functional expressionProteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cellsRelevance of Endoplasmic Reticulum Stress Cell Signaling in Liver Cold Ischemia Reperfusion InjuryDrugging the undruggables: exploring the ubiquitin system for drug developmentFrom epoxomicin to carfilzomib: chemistry, biology, and medical outcomesTargeted treatments for multiple myeloma: specific role of carfilzomibTargeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesThe ubiquitin/proteasome system mediates entry and endosomal trafficking of Kaposi's sarcoma-associated herpesvirus in endothelial cellsUbiquitination and proteasomal degradation of interferon regulatory factor-3 induced by Npro from a cytopathic bovine viral diarrhea virusCytopathic and Noncytopathic Interferon Responses in Cells Expressing Hepatitis C Virus Subgenomic RepliconsSynthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibitionElucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibitionOne-shot NMR analysis of microbial secretions identifies highly potent proteasome inhibitorHomopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome bindingEnzyme Inhibition by Hydroamination: Design and Mechanism of a Hybrid Carmaphycin-Syringolin Enone Proteasome InhibitorSystematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motifSelective inhibition of the immunoproteasome by ligand-induced crosslinking of the active siteThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingPathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathwaysProteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97Inhibition of proteasome activity strongly affects kiwifruit pollen germination. Involvement of the ubiquitin/proteasome pathway as a major regulatorA novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14The ubiquitin-proteasome pathway and proteasome inhibitorsAcute decreases in proteasome pathway activity after inhalation of fresh diesel exhaust or secondary organic aerosolProtein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells
P2860
Q24290224-D368E9EB-95E1-43D7-A05A-F0437C0327D3Q24294207-6E59E482-5991-45FB-8B6E-ECBC51B32210Q24296382-4A4233C6-1917-41F0-ADC9-D8533A8860D8Q24299947-26FAE910-423D-4EBA-BAF7-E99317989513Q24319714-7EDFEB11-D49D-4719-8662-05C37EC488ADQ24542503-AFF888BA-CD33-4B2C-B6E1-038CCD45F3DCQ24633116-DB8E7F2C-810C-4478-BDB4-53E50D80B699Q24643016-D4827F1A-9EC9-4D94-8780-9E08180A302BQ24644087-2DC0F61D-B4F2-4D62-A493-D78AE527A68FQ24645843-FBF079E4-9BA7-43DE-A4F0-4DD3FC88682FQ24654152-776070E1-5FE6-4D0C-A5FA-F279F74B0978Q24674865-C7388B9D-19C1-4891-A79A-AD8D4AE03012Q24675778-21DDFEB1-3B11-45B9-BA1D-6AF429F00CFCQ24683190-98BE6600-AF4F-4924-A679-C5FA4E1C8ABCQ24795923-A661F2AE-FED0-4C8E-A532-A3249D50BCDCQ24801210-61318E36-265E-4267-B76A-29D483B3B623Q26745583-D2B88C36-4777-48EA-8B19-A3D99F09D104Q26752823-A01A649A-6316-4D78-B647-DF9F6C7AD467Q26864557-D11FAF95-7A61-4F78-9169-764FDB470A10Q26996524-28144903-EF34-419B-8488-A5F73B7231D2Q27026951-D2BBA9E6-A25C-41F1-B8A5-6C95CB0340FFQ27345534-428F7F8A-3A22-4B50-BD0F-0028B84ED303Q27481222-BE69D1D8-26D5-4AC7-A4F2-F60D69B2BACDQ27485424-61595224-F716-485F-9B88-C7A0C7BD30CBQ27654628-DC28CBD4-5190-423B-89CD-44214BFFDB13Q27666372-365B2388-9A57-4962-BD15-318AB3935EB9Q27674685-77288E7D-2A83-41DD-864D-F566A0F0D74AQ27677425-7BD0A81F-E7FC-4E19-9751-EC7949CB4F21Q27684346-34A78E85-FE35-466D-A5F6-3B6D49A89172Q27688108-C4092E70-EEC0-4648-A2C0-A6A1FB36011DQ27695633-1C055F78-ED8B-4668-AD4A-FE3C209DCEB1Q28069789-F48ED068-8479-4FE3-BC3F-1938D87985BFQ28082335-D58232A8-E976-46D3-80F5-D41FE341B93CQ28235168-2B38C8A1-7CF0-4BBE-9240-EF1FA5AD91FCQ28243388-DC280628-3612-4E0E-881E-510F5ADD4809Q28344214-F878F125-8C82-4856-956F-0743AF89A60EQ28359750-A394E75F-2F17-4824-9D37-4BCFEE788D64Q28367002-10502135-163B-43E1-B380-CEC840E0D207Q28388522-917E05C4-D0AE-4165-A163-59AD8C285A21Q28475914-5D3BB1FC-E80B-4CDC-BB63-3AD20397B953
P2860
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@ast
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@en
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@nl
type
label
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@ast
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@en
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@nl
prefLabel
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@ast
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@en
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@nl
P2093
P2860
P3181
P356
P1476
Epoxomicin, a potent and selec ...... vivo antiinflammatory activity
@en
P2093
P2860
P304
P3181
P356
10.1073/PNAS.96.18.10403
P407
P577
1999-08-31T00:00:00Z